These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16422019)

  • 21. Olanzapine treatment of eight adolescent patients with psychosis.
    Ercan ES; Kutlu A; Varan A; Cikoğlu S; Coşkunol H; Bayraktar E
    Hum Psychopharmacol; 2004 Jan; 19(1):53-6. PubMed ID: 14716713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight gain due to long term antipsychotic treatment of persistent mental disorders.
    Tadger S; Melamed Y
    Psychiatr Danub; 2008 Mar; 20(1):37-41. PubMed ID: 18376329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expectations and developments in atypical antipsychotics].
    Praxis (Bern 1994); 2004 Aug; 93(35):1392. PubMed ID: 15468579
    [No Abstract]   [Full Text] [Related]  

  • 25. Olanzapine pamoate - blockbuster or damp squib?
    Taylor DM
    Int J Clin Pract; 2009 Apr; 63(4):540-1. PubMed ID: 19335703
    [No Abstract]   [Full Text] [Related]  

  • 26. [Mortality and cumulative exposure to antipsychotics, antidepressants and benzodiazepines in patients with schizophrenia: an observational follow-up study].
    Tiihonenl J; Mittendorfer-Rutz E; Torniainen M; Alexanderson K; Tanskanen A
    Duodecim; 2016; 132(2):181. PubMed ID: 26939492
    [No Abstract]   [Full Text] [Related]  

  • 27. Antipsychotic-induced weight gain: a review of the literature.
    Allison DB; Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 7():22-31. PubMed ID: 11346192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis.
    Block JJ
    Am J Psychiatry; 2006 Oct; 163(10):1838; author reply 1838. PubMed ID: 17012701
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study.
    Novick D; Haro JM; Suarez D; Marques-Teixeira J; Naber D
    Int Clin Psychopharmacol; 2008 Jul; 23(4):203-8. PubMed ID: 18545058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns.
    McClellan JM
    Am J Psychiatry; 2007 Oct; 164(10):1462-4. PubMed ID: 17898331
    [No Abstract]   [Full Text] [Related]  

  • 31. Olanzapine-associated pica in a schizophrenia patient.
    Huang JH; Shiah IS; Lee WK; Tzang RF; Chang KJ
    Psychiatry Clin Neurosci; 2010 Aug; 64(4):444. PubMed ID: 20653915
    [No Abstract]   [Full Text] [Related]  

  • 32. Olanzapine vs haloperidol for treatment of schizophrenia.
    Amin M; Shukla VS
    JAMA; 2004 Mar; 291(9):1065; author reply 1065-6. PubMed ID: 14996767
    [No Abstract]   [Full Text] [Related]  

  • 33. Olanzapine vs haloperidol for treatment of schizophrenia.
    Glazer WM
    JAMA; 2004 Mar; 291(9):1064-5; author reply 1065-6. PubMed ID: 14996766
    [No Abstract]   [Full Text] [Related]  

  • 34. Methodological concerns in a trial of ziprasidone and olanzapine.
    Ross DE
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
    [No Abstract]   [Full Text] [Related]  

  • 35. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
    Strassnig M; Miewald J; Keshavan M; Ganguli R
    Schizophr Res; 2007 Jul; 93(1-3):90-8. PubMed ID: 17478082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsychotic-associated weight gain and clinical outcome parameters.
    Blin O; Micallef J
    J Clin Psychiatry; 2001; 62 Suppl 7():11-21. PubMed ID: 11346191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
    Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
    Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 39. Olanzapine for schizophrenia.
    Med Lett Drugs Ther; 1997 Jan; 39(992):5-6. PubMed ID: 9008682
    [No Abstract]   [Full Text] [Related]  

  • 40. Review of atypical antipsychotics and weight gain.
    Sussman N
    J Clin Psychiatry; 2001; 62 Suppl 23():5-12. PubMed ID: 11603886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.